WILMINGTON, Del.--(BUSINESS WIRE)--Today, at the 2007 UBS Global Life Sciences Conference, Incyte Corporation (Nasdaq:INCY) will announce positive proof-of-concept clinical results from the following trials:
* a completed 28-day dose-escalation Phase Ib/IIa trial in mild-to moderate psoriasis using a topical formulation of INCB18424, its lead janus-associated kinase, JAK, inhibitor;
* an ongoing dose-escalation Phase Ib/IIa trial in myelofibrosis using the oral formulation of INCB18424; and
* an ongoing 28-day Phase IIa placebo-controlled two-step hyperinsulinemic clamp trial in Type 2 diabetes for INCB13739, its lead orally available 11beta-HSD1 inhibitor.
